0001493152-23-013393.txt : 20230424 0001493152-23-013393.hdr.sgml : 20230424 20230424171114 ACCESSION NUMBER: 0001493152-23-013393 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230424 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230424 DATE AS OF CHANGE: 20230424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rennova Health, Inc. CENTRAL INDEX KEY: 0000931059 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 680370244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35141 FILM NUMBER: 23840900 BUSINESS ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 561-855-1626 MAIL ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: CollabRx, Inc. DATE OF NAME CHANGE: 20120926 FORMER COMPANY: FORMER CONFORMED NAME: TEGAL CORP /DE/ DATE OF NAME CHANGE: 19950918 8-K 1 form8-k.htm
0000931059 false 0000931059 2023-04-24 2023-04-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 or 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): April 24, 2023

 

Rennova Health, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-35141   68-0370244
(Commission File Number)   (I.R.S. Employer Identification No.)

 

400 S. Australian Avenue, Suite 800, West Palm Beach,
Florida
  33401
(Address of Principal Executive Offices)   (Zip Code)

 

(561) 855-1626
(Registrant’s Telephone Number, Including Area Code)

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered under Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01. Regulation FD Disclosure

 

On April 24, 2023, Rennova Health, Inc. (the “Company”) issued a press release announcing that Seamus Lagan, our Chief Executive Officer, would be interviewed on Uptick Newswire’s “Stock Day” podcast with Kevin Davis. A copy of the press release is attached hereto as Exhibit 99.1 and a transcript of the interview is attached hereto as Exhibit 99.2.

 

The information furnished pursuant to this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits

 

  (d) Exhibits

 

Exhibit No.   Exhibit Description
     
99.1   Press Release dated April 24, 2023
     
99.2   Transcript of Interview of Seamus Lagan
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 24, 2023 RENNOVA HEALTH, INC.
     
  By: /s/ Seamus Lagan
    Seamus Lagan
    Chief Executive Officer
    (principal executive officer)

 

3

 

EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

 

RENNOVA HEALTH, INC. PROVIDES UPDATE AFTER FILING 2022 FINANCIAL STATEMENTS

 

WEST PALM BEACH, Fla. (April 24, 2023) – Rennova Health, Inc. (OTC: RNVA) Chief Executive Officer Seamus Lagan recently joined Stock Day host Kevin Davis to provide an update after filing the 2022 financial statements and other information in its Form 10-K with the SEC.

 

Davis began the interview by asking Lagan to remind his listeners what the Company does. Lagan explained the current business operations in rural healthcare and the plans to open a mental and behavioral facility at its hospital.

 

Davis went on to ask about what he saw as a significant improvement from previous years, in the recently filed financial results.

 

Lagan pointed out that revenues improved by over $10 million and were up from approximately $3.2 million in 2021 to just over $13 million in 2022. He also pointed out an $11.5 million reduction in losses from continuing operations before other income (expense) and income taxes. These losses were reduced from approximately $12.5 million in 2021 to just over $1.4 million in 2022. Lagan continued to say that he believed there would be a continued improvement in revenue from current operations and hoped to add new revenue this year from the new mental and behavioral health division.

 

Davis followed by asking for an update on the timeframe for opening Myrtle Recovery Centers and reminded listeners that we had previously launched a new web site for this project at www.myrtlerecoverycenters.com

 

Lagan replied that opening was well on track for the second quarter and went on to describe the project in three parts, the facility, licensure with the State, and the employees required. He described that work onsite is complete and the facility is ready to accept patients. The licensure process is at an advanced stage with only a fire inspection required by the State to finalize a pre-opening site visit. He voiced a belief that the fire inspection will be completed in a matter of days and that he could see no reason why a pre-opening site visit by the State will not result in the granting of the license. He also explained that the total employed will start at approximately 14 and grow to approximately 25 when the facility is at full capacity and stated that there is an experienced CEO running the project, that adequate employees have been secured to open and that adequate applications have been received to staff the facility for full capacity. He explained that it was expected that most of the patients at this initial 30 bed facility will be paid for by Medicaid or Medicare and confirmed his belief that the project could add significant and profitable revenues to Company operations.

 

 

 

 

Davis then asked about the investment Rennova held in InnovaQor (INQR) and asked for an explanation to help his new listeners understand this structure.

 

Lagan explained the previous separation of a software division into InnovaQor and explained that InnovaQor had an exciting project underway for the development of a medical professional’s communication network. He described that this network should generate significant revenues from subscription fees. He further described the intention, subject to meeting the relevant regulations and requirements, to distribute some of the investment in InnovaQor, to the Rennova shareholders and stated his belief that Rennova will shortly start to get repaid the money it has provided to support the project.

 

Davis ended the interview by asking Lagan what message he would like the Company’s shareholders to take away from the interview. Lagan responded by saying that he hoped the listeners would see the progress that has been in the past year and that continued progress would be made for the remainder of this year.

 

To hear Seamus Lagan’s entire interview, follow the link to the podcast here:

 

https://audioboom.com/posts/8286271-rnva-ceo-seamus-lagan-is-featured-on-the-stock-day-podcast

 

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/

 

About Rennova Health, Inc.

 

Rennova Health, Inc. (“Rennova,” the “Company,” “we”, “us”, “its” or “our”) is a provider of health care services. The Company owns an operating hospital in Oneida, Tennessee known as Big South Fork Medical Center, a hospital located in Jamestown, Tennessee that it plans to reopen, and a rural clinic in Kentucky. For more information, please visit www.rennovahealth.com

 

Forward-Looking Statements

 

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

 

Contact:

 

Rennova Health

561-855-1626

info@rennovahealth.com

 

 

 

 

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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ex99-2.htm

 

Exhibit 99.2

 

Rennova Health, Inc. (RNVA) Interview
CEO Seamus Lagan on Uptick Newswire – April 2023

 

Speakers: Kevin Davis and Seamus Lagan

 

Davis: On today’s show we’re bringing back a returning guest, they were last with us in February of 2023. The name of the company is Rennova Health, Inc. They trade on the OTC Exchange under the ticker symbol ‘RNVA’. With us today is the company’s CEO, Mr. Seamus Lagan. Seamus, welcome back to the show.

 

Lagan: Thanks Kevin, it’s nice to be back. I appreciate the opportunity.

 

Davis: Before we get started on the Q & A and get updates today, I would like to get an updated “about statement” so that our new listeners can get up-to-speed with what your company does.

 

Lagan: Thanks for that Kevin. The company is in rural healthcare; we own an operating rural hospital in Tennessee and we are in the process of opening a behavioral health facility at that facility. We have had a couple of difficult years, this is a turnaround situation we believe and we think that our recent financial filings support what we’ve been saying, that it has been an improving situation.

 

Davis: I want to congratulate you for getting your 10-K filed on time. In my opinion, it shows significant improvement in revenues and operations from the previous years. I know we touched on that in our last interview with you. We were looking forward to getting an update on it. Can you tell me about that?

 

Lagan: Of course, Kevin, thanks. First of all, it was good to get filed. It did go down to the line but it got filed. I believe it does demonstrate the improvements that we have been speaking about, including in the last podcast. The revenues were up from approximately $3.2 million in 2021 to just over $13 million in 2022. That is a $10 million increase, so that was a good achievement on our part we believe. Probably more important is the reduction in losses from continuing operations, before other income (expenses) and income taxes. These were $12.5 million in 2021 and that loss has reduced to just over $1.4 million in 2022. So, that was an improvement of approximately $11.5 million. With regard to operations, we believe we can continue to grow the current revenue from our existing operations and we are working to add new revenue this year from Myrtle Recovery Centers - our new mental and behavioral health division. So, we’re optimistic that we can deliver a continued increase in revenues and get these operations profitable. Kevin, there are always hurdles to overcome but we are confident we have a model that works and will be well proven if we can access some new capital to duplicate it.

 

Davis: You know, I want to shift gears. Let’s go back to our previous interview - we talked about Myrtle Recovery Centers. On February 23, you told us that the company launched a site called myrtlerecoverycenters.com. I want to get an update on the behavioral health division, because I know you predicted an opening in the second quarter of 2023. Where are we at with that?

 

 

 

 

Lagan: As you say, we have previously indicated that this should open in the second quarter. Bluntly, we remain well on track to meet that time frame. There are three parts to this project: the facility, the licensure with the state, and the employees required. Work on site is complete - the facility is looking good and ready to accept patients. That is the first part. The licensure process is at an advanced stage with only a fire inspection required by the state to finalize a pre-opening site visit. We believe the fire inspection will be completed in a matter of days and we see no reason why a pre-opening site visit by the state would not result in the granting of the license. The total employed at the start of this project will be approximately 14 people and should grow to about 25 when we are at full capacity. We have an experienced CEO running the project, have secured adequate employees to open, and have more than adequate applications and interest to enable us to staff the facility when we are at full capacity. So, we believe we are well on schedule to open this within the second quarter. We also expect that most of our patients at this first, relatively small, 30-bed facility will be paid for by Medicaid or Medicare, and we believe it has the ability to add significant profitable revenues to our existing operations.

 

Davis: Incredible. I know another thing people have been excited about is the significant investment in your software division, which is called InnovaQor. They actually trade on the OTC Exchange under the ticker symbol ‘INQR’, so you definitely have some diversification there. I am wondering if you can give me an update on that and before you do, just kind of explain that overall structure to our new listeners.

 

Lagan: That was a software division that was underneath Rennova and we felt that we weren’t making the best progress that that division could make under Rennova, so it got separated out into what is now InnovaQor. They have an exciting project underway for the development of a medical professional’s communication network, specifically for people in the healthcare industry. Currently, small revenues and the company looks small, but that is an exciting project and we believe it will get funded and it will get off the ground fairly quickly. That network should generate significant revenues from subscription fees from added value solutions for that healthcare sector when it’s up and running. From our perspective, it is still our intention, subject to meeting the relevant regulations and requirements, to distribute some of the investment we have in InnovaQor to the Rennova shareholders. We can’t really commit to a timeframe as we speak, but we will get this done and it will be done as soon as practical and possible. That would mean as a return, we believe Rennova will shortly start to get repaid the money it has provided to support the project and we believe that our Rennova shareholders will also benefit from being shareholders directly in that project when it is a little further progressed.

 

Davis: You’ve been listening to Seamus Lagan, he has been updating us on Rennova Health - they trade on the OTC Exchange, under the ticker symbol ‘RNVA’. You can also visit them online at rennovahealth.com – they have a very nice interactive website with lots of information. Before we part ways for the day, I want to get a message from you. What do you want folks to take away from this interview before we see you again in 30 to 45 days?

 

Lagan: Kevin, I’d like listeners to continue to see the progress that we have made, particularly over the last year and that we hope to make. I think the message I am hoping they hear is that we expect to make continued progress in the immediate future - this year and beyond, that will see this company grow into something much more significant very shortly. Hopefully we can deliver some value, some opportunity for investors and shareholders as we continue to focus on that growth.

 

Davis: Well Seamus, I look forward to speaking with you in the next 30 to 45 days. I want to remind everybody, go to rennovahealth.com, check them out on the OTC Exchange under the ticker symbol ‘RNVA’. It has been an absolute pleasure today, thank you so much.

 

Lagan: Thank you, Kevin. I appreciate it.

 

2

EX-101.SCH 5 rnva-20230424.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 rnva-20230424_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 rnva-20230424_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Apr. 24, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 24, 2023
Entity File Number 001-35141
Entity Registrant Name Rennova Health, Inc.
Entity Central Index Key 0000931059
Entity Tax Identification Number 68-0370244
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 400 S. Australian Avenue
Entity Address, Address Line Two Suite 800
Entity Address, City or Town West Palm Beach
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33401
City Area Code (561)
Local Phone Number 855-1626
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000931059 2023-04-24 2023-04-24 iso4217:USD shares iso4217:USD shares 0000931059 false 8-K 2023-04-24 Rennova Health, Inc. DE 001-35141 68-0370244 400 S. Australian Avenue Suite 800 West Palm Beach FL 33401 (561) 855-1626 false false false false false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &:)F%8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !FB9A65?ZCJ.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R';*&";-I:.G#@8K;.QF;+4UBQ-C:R1]^SE9FS*V!]C1TN]/ MGT"U"4G_$(09L/ M?420G-^#1])6DX8)6(2%R)K:&F4B:NKC!6_-@@^?L9UAU@"VZ+&C!*(4P)II M8CB/;0TWP 0CC#Y]%] NQ+GZ)W;N +LDQ^26U# ,Y5#-N;R#@+>GW-^RQK)957P52%7>RF4$(H_O$^N/_QNPKZW[N#^ ML?%5L*GAUUTT7U!+ P04 " !FB9A6F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M &:)F%9CI"'; 0 %H/ 8 >&PO=V]R:W-H965T&UL MC9=1;^(X$,??]U-86>ET)Q42AT"A!TB4MK?5=G=1Z5VE.]V#20Q8F]A9VX'V MV]\XT(3MA8$\0)QX_OEE9C)C#[=*?S=KSBUYR5)I1M[:VOS*]TV\YADS;95S M"7>62F?,PE"O?)-KSI+2*$O], AZ?L:$],;#\MI,CX>JL*F0?*:)*;*,Z==K MGJKMR*/>VX5'L5I;=\$?#W.VXG-N_\QG&D9^I9*(C$LCE"2:+T?>A%Y=AZ$S M*&?\)?C6')P3]RH+I;Z[P7TR\@)'Q%,>6R?!X&_#ISQ-G1)P_-B+>M4SG>'A M^9OZ7?GR\#(+9OA4I<\BL>N1U_=(PI>L2.VCVG[B^Q?J.KU8I:;\)=O=W"CR M2%P8J[*],1!D0N[^V$0<&X>"(0;@W*!WA[QY44MXPR\9#K;9$N]F@YD[* M5RVM 4Y(%Y6YU7!7@)T=3]6&ZZ%O0I*?A>L.]\2\? M:2_X'>'K5'P=3'U\H^("<-\'AYOW69P0BJB B5&4"!$E)<9>R51,% M;K]DJ>$(1[?BZ)[GC!G70B7D5B8$DJ_1+[A2E4:G\JA7H?50P5MIA7TE=R+E MY&N1+9IS&]<( MKJ=&E$$9[+BN?R')Y'OA(NL\%G7UG6Z"A%(*I60JJ"7\AG_EK$R"N%, QZ-"@.T"P!A76X!RL M)_9"[A-@$TL1L[*('X\IKMCKMX+.91!&$8)'@[IH!N< 0A24SI4NV2[(W,)' M0)0F4U6 0\&O*FF,]0GUFUL,\J"RTW,@)TD"]=!8XAUEZ!XF7^/6*7E3*N-D'%SX''- MNP<,K6X<%*_W[]%FREBH.W^+_/BW@BMV.E& %6I:=PZ*E_TRDA-8V1Y'P05^ M[?;H;QA*W30H7NT?5 Q>F:V5Q+K8"9%^M]NBO;"'$=5]@N+E_5D+:[D$UV19 M(??5V#12X4*GUB"T[A$4+^ESE8I86"%7Y LDN!8L;>3!54[QA'5/"/&J/=.\ M%8-[.'QANZ4BK-9@4?MMN6R.WPF]DV1U(PCQJOT_LGMC"B ["8C+G@0\6/R? M5?5O,ZY7+IY_@()=NV3+F6Q%LK 5*T_7L/GEVDV ^TNE[-O [<>J[?3X/U!+ P04 " !F MB9A6GZ ;\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2 M,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B M6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG- M@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3T MXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(? M]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I M^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE< MA!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=> MBD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T

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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://rennovahealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm ex99-2.htm rnva-20230424.xsd rnva-20230424_lab.xml rnva-20230424_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 20 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "rnva-20230424_lab.xml" ] }, "presentationLink": { "local": [ "rnva-20230424_pre.xml" ] }, "schema": { "local": [ "rnva-20230424.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "RNVA", "nsuri": "http://rennovahealth.com/20230424", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-04-24to2023-04-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://rennovahealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-04-24to2023-04-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001493152-23-013393-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-013393-xbrl.zip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end